Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis.
Cutaneous leishmaniasis has been recognized as a major public health problem in several countries. Pentavalent antimonies, meglumine antimoniate and sodium stibogluconate, have been considered as standard treatment for leishmaniasis. Side effects have been reported to be increased hepatic enzyme levels and electrocardiographic abnormalities. We performed this study to evaluate the influence of meglumine antimoniate on some liver, kidney, and pancreas function tests. Eighty patients fulfilled the study criteria. Forty-one (51.3%) patients were female and the mean age of the patients was 30.4 +/- 15.7 years. Blood samples were taken to evaluate liver, kidney, and pancreas function tests before and after treatment with intramuscular injections of MA at a dose of 20 mg Sb(+5)/kg/day for 15 days. Mean serum levels of blood urea nitrogen, creatinine, sodium, total and direct bilirubin, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase significantly increased after treatment, although most of them were within normal ranges. There were no significant differences in serum levels of potassium, amylase, lipase, and gamma-glutamyl transpeptidase before and after treatment. In conclusion it can be stated that one course of treatment with 20 mg Sb(+5)/kg/day MA for 15 days does not significantly alter the liver, kidney and pancreas function tests in patients with cutaneous Leishmaniasis.
Kashani
Mansour Nassiri
MN
Medical Sciences/University of Tehran, Center for Research and Training in Skin Diseases and Leprosy, Tehran, Iran. nasirika@sina.tums.ac.ir
Firooz
Alireza
A
Eskandari
Seyed Ebrahim
SE
Ghoorchi
Mohammad Hossein
MH
Khamesipour
Ali
A
Khatami
Alireza
A
Javadi
Amir
A
Dowlati
Yahya
Y
D000293:Adolescent; D000328:Adult; D000681:Amylases / Q000097:blood; D000981:Antiprotozoal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000097:blood; D004573:Electrolytes / Q000097:blood; D005260:Female; D006801:Humans; D007267:Injections; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D016773:Leishmaniasis, Cutaneous / Q000097:blood / Q000188:drug therapy*; D008049:Lipase / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008111:Liver Function Tests; D008297:Male; D008536:Meglumine / Q000494:pharmacology* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism
D000981:Antiprotozoal Agents; D004573:Electrolytes; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D003404:Creatinine; D008049:Lipase; D000681:Amylases